Health Professionals and Partners

Skip to Content

North Bay Parry Sound District Health Unit Logo North Bay Parry Sound District Health Unit Logo Print

Contact Us
  • Public Health
    Services
    • Breastfeeding Clinic
    • Community Events and Farmers Markets
    • Dental Clinic
    • Family Health Information Line
    • Food Safety Certification Training
    • Healthy Babies, Healthy Children
    • Infection Prevention and Control Investigations
    • Inspection Results and Enforcement
    • Needle Syringe Program
    • Parenting Workshops
    • Prenatal Classes
    • Private Drinking Water Testing
    • The Sexual Health Clinic
    • Vaccination Clinics
    • Vaccination Records
    • Vision Screening
  • Health
    Topics
    • 2SLGBTQ+
    • Air Quality
    • Alcohol
    • Animal Bites
    • Beach, Lake and Pool Water
    • Breastfeeding
    • Cancer Prevention and Screening
    • Climate Change
    • Dental Health
    • Diseases
    • Drinking Water
    • Emergencies and Being Prepared
    • Farm Fresh Eggs
    • Flu/Influenza
    • Food Poisoning
    • Food Safety
    • Gambling
    • Healthy Aging
    • Healthy Eating
    • Heat and Humidity
    • Home Health and Safety
    • Housing and Homelessness
    • Injury Prevention
    • Intimate Partner Violence
    • Mental Health
    • Naloxone
    • Parenting
    • Perfluoroalkylated Substances (PFAS)
    • Physical Activity
    • Pregnancy
    • Racism
    • Reducing Weight Bias
    • Sexual Health
    • Sharps
    • Smoking, Vaping and Tobacco
    • Substance Use
    • Suicide Prevention
    • Vaccinations
    • Youth Engagement – IMPACT
  • Health Professionals
    and Partners
    • Camp Providers
    • Child Cares
    • COVID-19 Healthcare Providers, Hospitals and Long-Term Care
    • Designated Officers
    • Emergency Management
    • Group Home and Shelter Administrators
    • Health Care Professionals
    • Health Care Providers COVID-19 Vaccine Information
    • Long-Term Care and Retirement Homes
    • Municipal Resources
    • Nutrition Resources
    • Ontario Naloxone Program (ONP) Distributing Agencies and First Responders
    • Personal Service Settings
    • Report an Overdose
    • Schools
    • Teaching Kitchen
  • Community Data
    and Reports
    • Chronic Diseases
    • Environmental Health
    • Health Behaviours
    • Indirect Impacts of COVID-19
    • Infectious Diseases
    • Injuries
    • Mortality
    • Nipissing Parry Sound Public Health Atlas
    • Oral Health
    • Population Demographics
    • Reproductive and Child Health
    • Substance Use Reporting
    • Well-being and Mental Health
  • About Us
    • About Us
    • Accessibility
    • Board of Health
    • Careers and Placements
    • Contact Us
    • News and Events
    • Personal Health Privacy Policy
    • Programs and Services
    • RFPs and Tenders
Search Button

Back To Top

Tuberculin Skin Testing Guide

Home...Health Care ProfessionalsCommunicable Disease ControlTuberculin Skin Testing Guide
  • Open new window to share this page via Facebook Facebook
  • Open new window to share this page via Twitter Twitter
  • Open new window to share this page via LinkedIn LinkedIn
  • Email this page Email

 Tuberculosis Infection (latent) and active/suspect cases of tuberculosis are reportable to the Health Unit.

Report a Case

 

What is Tuberculosis?

Tuberculosis (TB) is an infection with Mycobacterium tuberculosis acquired by inhalation of bacilli-containing droplet nuclei small enough to reach the alveoli. Most individuals’ immune systems are able to eradicate the bacteria, while others replicate it and develop TB infection.

Active TB disease is defined as disease in a person with infection in whom symptoms, signs, and/or radiographic evidence caused by M. tuberculosis complex are apparent; disease may be pulmonary, extrapulmonary, or both.

How is it Transmitted?

Transmission of M. tuberculosis occurs mostly (with very few exceptions) via droplet nuclei which can then be inhaled by those who are exposed. For this reason, only those with active pulmonary and/or laryngeal TB disease are likely to be contagious.

The probability of transmission increases with bacterial burden, amount and severity of cough in the source case, duration of exposure, proximity to source case, crowding and room ventilation, and delays in diagnosis and/or effective treatment.

Symptoms

  • A chronic cough of at least 2 to 3 weeks' duration that is initially dry but after several weeks to months will become productive.
  • Fever and night sweats are common but may be absent from the very young and elderly.
  • Hemoptysis, anorexia, weight loss, chest pain, and other symptoms are general manifestations of advanced disease.

Tuberculosis infection (latent)

The bacteria M. tuberculosis is present in the lungs, but can survive for years in a dormant state. A person with TB infection does not have active disease, is asymptomatic, and is not contagious. TB infection can develop into active disease at any time.

Identification and treatment of TB infection can substantially reduce the risk of development of active TB disease.

Testing

The goal of testing for TB infection is to identify individuals who are at increased risk for the development of active TB disease, and therefore, would benefit from treatment of TB infection.

There are two acceptable tests for identification of TB infection:

  • Tuberculin skin test (TST)
  • Interferon Gamma Release Assay (IGRA)

Refer to Chapter 4: Diagnosis of Tuberculosis Infection of the Canadian Tuberculosis Standards, 8th edition (2022) for more information or contact the Communicable Disease Control Program.

Screening and Treatment

Screening for TB infection should be undertaken only when there is a commitment to treatment or monitoring, should the test results be positive.

Treatment for TB infection should be individualized and based on the risk of prior TB exposure and risk of reactivation. Active TB disease must carefully be ruled out prior to starting TB infection treatment.

See international TB rates by country

Tuberculin Skin Testing (TST)

The TST consists of the intradermal injection of a small amount of purified protein derivative (PPD) from M. tuberculosis bacteria.

In a person who has cell-mediated immunity to these tuberculin antigens, a delayed hypersensitivity reaction will occur within 48 to 72 hours. The reaction will cause localized swelling and will manifest as induration of the skin at the injection site.

The use of TSTs or IGRAs for the diagnosis of active TB disease in adults is not recommended.

Two-Step TST

A two-step TST is useful for the initial skin testing of adults who are going to be retested periodically (e.g., healthcare workers), due to an elevated risk of exposure.

These persons should undergo a two-step TST prior to any exposure to account for the booster effect. This is because the initial TST may elicit an immune response in persons with remote TB infection or prior Bacille Calmette-Guerin (BCG) vaccination.

This "booster" immune response results in a greater response if a second TST is administered anytime from a week to more than a year later.

The two-step protocol needs to be performed and documented ONCE. Any subsequent TST should be a one-step, regardless of how long it has been since the last TST.

A second test should be performed 1 to 4 weeks after the first test using the same materials and techniques to administer and read the TST.

The Health Unit offers TSTs to specific populations:

  • post secondary students who need a TST to be admitted to or continue with a program
  • people under the age of 65 entering a Long Term Care Home
  • medically necessary TSTs covered under OHIP for contact tracing, refugees and homeless/ underhoused
  • clients who have proof from a doctor who need the testing as part of a medical assessment or treatment plan

Contact the Vaccine Preventable Diseases (VPD) program at 705-474-1400 or 1-800-563-2808 ext. 5252 or email at vpd@healthunit.ca.

Contraindications

Do NOT give a TST to someone who has:

  • Severe blistering TST reactions in the past
  • Extensive burns or eczema present over TST testing sites
  • A current major viral infection (e.g., measles, mumps, varicella)
  • Documented active TB disease or a well-documented history of adequate treatment for TB infection or disease in the past
  • Received live virus immunization with the past 4 weeks

Vaccination with live viruses may interfere with TST reactions. For persons scheduled to receive a TST, testing should be done as follows:

  • Either on the same day as vaccination with live-virus vaccine
  • Or at least 1 month after the administration of the live-virus vaccine

For more information see TST fact sheet

Note: If the opportunity to perform TST might be missed, TST should not be delayed for live virus vaccines. TST may be administered before or on the same day as the live-virus immunizations, but at a different site.

Who can receive a TST

A TST CAN be given to those who:

  • Are pregnant or breastfeeding
  • Have a history of receiving a BCG vaccine
  • Have a previously positive TST
  • Are taking low doses of systemic corticosteroids (<15mg prednisone or equivalent daily)
  • Have a common cold
  • Have had an immunization the same day (TST should be administered at a different site)
  • Were immunized within the previous 4 weeks with vaccines other than live virus vaccines

Steps to Conducting a TST:

Step 1: Administering

Locate and Clean

  • Use inner aspect of forearm, 10 cm (4 inches) below elbow, preferably on the non-dominant arm. If neither forearm is suitable, use the outside of the forearm or the upper arm
  • Avoid areas with abrasions, swelling, visible veins, lesions, rash, eczema, burns, or tattoos
  • Clean area with alcohol swab and let air dry
  • Do not use EMLA® or other local anesthetic cream on area being tested

Prepare

  • 5 tuberculin units of Tubersol® PPD-Standard is recommended in Canada
  • Check expiry date and ensure vials are labelled with dates when opened
  • Use a 0.6 to 1.3 cm (1/4 -1/2 inch), 26 or 27 gauge needle with a disposable plastic tuberculin syringe
  • Draw up solution just prior to injecting it. Do not preload syringes.
  • Withdraw a little more than 0.1 mL of tuberculin solution from vial under aseptic conditions
  • Expel one drop and ensure that 0.1 mL remains in syringe
  • PPD should be stored between 2 to 8 degree Celcius and the syringe should be placed under a towel to maintain darkness prior to injecting; except when doses are actually being withdrawn from the vial

Inject

  • Hold skin taut. Position the bevel of the needle facing up. Insert needle intradermally at a 5 to 15 degree angle to the skin, without aspirating. The tip of the needle will be visible just below  the surface of the skin. Insert the needle until the entire bevel is covered.
  • Inject 5 tuberculin units (0.1mL) of Tubersol® PPD-Standard, slowly.
  • A 6 to 10 mm wheal (discrete, pale elevation of the skin) should appear.
  • The size of the wheal is not completely reliable, but if a lot of liquid runs out and there is no wheal, then repeat the injection on the opposite forearm or 5 cm away from the initial injection site on the same forearm.
  • A drop of blood is normal. Do not massage area.

Teach Client

• Do not cover with bandage

• Do not scratch site

• Perform all normal activities, including showering and bathing, but do not scrub area

• Wheal often disappears within 15 minutes

Client must return 48 to 72 hours after administration for reading by a trained healthcare professional. 

Document:

•  Date and time of injection

•  Tuberculin dose, manufacturer, lot number, and expiry date

•  Site of injection

•  Person administering the TST

Monitor

Monitor client for 15 minutes post-injection in case of allergic reaction. Although very rare, be prepared to manage anaphylaxis.

Step 2: Reading

  • A healthcare professional trained to read TSTs should read the test within 48 to 72 hours after administration.
  • If the TST cannot be read within 48 to 72 hours after administration, it should be repeated at a location far enough from the previous test that the reactions do not overlap. No minimum wait time is required before repeat testing.

Inspect

  • Support the forearm on a firm surface and flex slightly at the elbow.
  • Look for induration (a hard, dense, raised formation). Note that induration is not always visible.

Palpate

  • Use fingertips to check if induration is present.

Mark

  • To mark the border of the induration, move the tip of a pen at a 45 degree angle laterally toward the site of the injection
  • The tip will stop at the edge of the induration if it is present
  • Repeat this on the opposite side of the induration

Measure

  • Use a caliper (TB ruler) to measure the distance between the pen marks at the widest transverse diameter (at a right angle to the long axis of the forearm)
  • Measure induration in millimetres (mm). Record no induration "0 mm". Avoid words such as "positive", "negative", "reactive", or "non-reactive"
  • If the measurement falls between demarcations on the ruler, record the lower measurement. Do not round off the diameter of the induration to the nearest 5 mm
  • Do NOT measure erythema (redness). Redness does not indicate TB infection and is not a contraindication to future TSTs

Document

  • Date induration is read
  • Measurement of the induration, if any, in millimetres (mm)
  • Record any adverse reactions (e.g., blistering)
  • Name of the individual reading the test

Step 3: Interpreting TST Results

False-positive reactions:

Some persons may react to the TST even though they are not infected with M. tuberculosis. The causes of these false-positive reactions may include, but are not limited to:

  • Previous TB vaccination with the BCG vaccine (IGRA blood tests are preferred over TST for those that have had a previous BCG vaccination)
  • Infection with non-tuberculous mycobacteria
  • Incorrect measurement or interpretation of reaction
  • Incorrect antigen used

False-negative reactions:

Some individuals that are infected with M. tuberculosis may not react to the TST. Reasons for this false-negative reaction may include, but are not limited to:

  • Anergy (absence of the normal immune response to a particular antigen)
  • Recent TB infection (within the past 8 to 10 weeks)
  • Very young age (younger than 6 months)
  • A weakened immune system due to a Human Immunodeficiency Virus (HIV) infection
  • Active TB disease, or if they have recently been infected by a person with active TB disease (it takes 3 to 8 weeks after exposure for a TST to become positive)
  • Recent live-virus measles or smallpox vaccination
  • Incorrect method of administering
  • Incorrect measuring or interpretation of TST reaction

Interpretation of a positive or negative TST

Interpreting a TST result primarily depends on the clinical context. There are multiple dimensions to consider when faced with a positive or negative TST to help decide whether someone is at risk of developing TB disease. These include the pretest probability that the person is truly infected, the individual risk of TB disease, and the ability of the test to identify persons at risk of disease. Refer to Chapter 4: Diagnosis of Tuberculosis Infection of Canadian Tuberculosis Standards, 8th edition for more information.

The online TST/IGRA Interpreter interactive algorithm incorporates all three dimensions discussed above and is highly recommended when deciding on TB infection treatment.

TB infection and active/suspect cases of TB are reportable to the CDC Program.

Step 4: Managing a Positive TST

Management of a positive TST should occur in two distinct steps:

  1. Decide that a TST is positive:
    • Determine if the TST is positive by reviewing the dimensions from Step 3 and the criteria in Table 1 below
    • Investigate further to rule out a false positive
    • If a TST is considered positive, the individual should be referred for medical evaluation

  2. Medical Evaluation

    • Assess signs and symptoms suggestive of possible active TB disease, assess patient risk factors, and order chest radiography
    • In the presence of symptoms or abnormal chest x-ray, collect 3 sputum samples at least 1 hour apart for acid-fast bacilli (AFB) smear and culture
    • Testing for active TB disease is indicated when someone has signs and symptoms of TB, and when an individual is considered to be high-risk
    • Diagnosis of TB infection is made if a person has a positive TST result, and a medical evaluation does not indicate TB disease. The decision about treatment for TB infection is based on a person's chances of developing TB disease, by considering their risk factors.

TB infection and active/suspect cases of TB are reportable to the CDC program.

Size of Induration

Table 1: Interpretation of TST Results
TST Result Situation in which a reaction is considered positive:
 

These groups are more at risk of developing TB infection and/or active TB disease.

>5 mm
  • People living with HIV
  • A recent contact of a person with active TB disease
  • People with chest x-ray findings suggestive of previous TB disease
  • People with organ transplants
  • Other immunosuppressed people (e.g., patients on prolonged therapy with corticosteroids equivalent to/greater than 15mg per day of prednisone or those taking Tumor Necrosis Factor antagonists [TNF-antagonists])
>10 mm
  • People born in countries where TB disease is common (including Mexico, the Philippines, Vietnam, India, China, Haiti, and Guatemala, or other countries with high rates of TB)
  • People who abuse drugs
  • People who live or work in high-risk congregate settings (e.g., nursing homes, homeless shelters, or correctional facilities)
  • People with certain medical conditions that place them at high risk for TB (e.g., silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and certain intestinal conditions)
  • People with low body weight (<90% of ideal), children younger than 5 years of age, and infants, children, and adolescents exposed to adults in high-risk categories
>15 mm
  • People with no known risk factors for TB

NOTE: A negative TST or IGRA is expected in up to 30% of children with TB and should not be used to exclude diagnosis. Consider consultation with an infectious disease specialist if there are concerns regarding TB in this population.

Summary of recommended treatment regimens for TB infection (latent)
RegimenDurationDoseFrequencyCommon Side Effects

First-line regimens

Rifapentine and Isoniazid (3HP)

3 months (12 doses)

Isoniazid:

15mg/kg

Maximum: 900mg

Rifapentine:

10-14.0 kg: 300mg

14.1-25.0 kg: 450mg

25.1-32.0 kg: 600 mg

32.1-49.9 kg: 750 mg

≥50.0 kg: 900mg

Maximum: 900mg

Once weekly Flu-like reactions, drug interactions
 Rifampin (4R)  4 months (120 doses)

10mg/kg

Maximum: 600 mg 

 Daily Rash, drug interactions

Second-line regimen

Isoniazid (9H)

 

9 months (270 doses)

 

5mg/kg

Maximum: 300mg

 

Daily 

 

Hepatoxicity, peripheral neuropathy 

Alternative regimens

Isoniazid (6H)

 

6 months (180 doses)

 

5mg/kg

Maximum: 300mg

 

Daily

 

Hepatoxicity, peripheral neuropathy

Intermittent Isoniazid for 9 months 9 months (78 doses)

15 mg/kg

Maximum: 900mg

Twice weekly Hepatoxicity, peripheral neuropathy
Isoniazid and Rifampin (3HR) 3 months (90 doses)

Isoniazid: 

5mg/kg

Maximum: 300mg

Rifampin: 

10mg/kg

Maximum: 600mg

Daily Hepatoxicity, peripheral neuropathy, drug interactions

Resources

Canadian Sources

  • Canadian Lung Association
  • Canadian Thoracic Society (CTS) of the Canadian Lung Association (CLA); Public Health Agency of Canada (PHAC). (2022). Canadian Tuberculosis Standards. 8th edition
  • Ontario Agency for Health Protection and Promotion (Public Health Ontario), Provincial Infectious Diseases Advisory Committee. 1st revision: April 2015. Infection Prevention and Control for Clinical Office Practice.
  • Public Health Agency of Canada
  • Ontario Hospital Association. TB Protocol, June 2018
  • Ontario Ministry of Health and Long Term Care: Routine Practices and Additional Precautions in All Health Care Settings
  • Recognizing BCG versus smallpox scars
  • Stop TB Canada

American Sources

  • Centers for Disease Control and Prevention
  • Core Curriculum on Tuberculosis: What the Clinician Should Know
  • Tuberculosis Education and Training Network

International Sources

  • World Atlas of BCG Policies and Practices
  • World Health Organization, Tuberculosis Profile: Canada (2021)

References

  • Centres for Disease Control and Prevention. (2020). Tuberculin Skin Testing.
  • Public Health Agency of Canada. (2022). Tuberculosis: For health professionals.
  • Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, (2022). Canadian Tuberculosis Standards, 8th edition.

Communicable Disease Control Program

705-474-1400 or 1-800-563-2808 ext. 5229 

cdc@healthunit.ca

Vaccine Preventable Diseases Program

705-474-1400 or 1-800-563-2808 ext. 5252
vpd@healthunit.ca

Health Professionals and Partners
    • Camp Providers
      Toggle Section Camp Providers Menu
      • Cleaning Recommendations During an Outbreak
    • Child Cares
    • COVID-19 Healthcare Providers, Hospitals and Long-Term Care
    • Designated Officers
    • Emergency Management
      Toggle Section Emergency Management Menu
      • Municipalities
      • Personal Preparedness
        Toggle Section Personal Preparedness Menu
        • Emergency Kits
        • Resources
    • Group Home and Shelter Administrators
    • Health Care Professionals
      Toggle Section Health Care Professionals Menu
      • Breastfeeding resources
      • Communicable Disease Control
        Toggle Section Communicable Disease Control Menu
        • C. Difficile
        • MRSA
        • Tuberculin Skin Testing Guide
      • Harm Reduction
      • Local Influenza Activity
    • Health Care Providers COVID-19 Vaccine Information
    • Long-Term Care and Retirement Homes
      Toggle Section Long-Term Care and Retirement Homes Menu
      • Communicable Disease Outbreaks in Long-Term Care Settings
    • Municipal Resources
    • Nutrition Resources
      Toggle Section Nutrition Resources Menu
      • Adventures in Cooking
    • Ontario Naloxone Program (ONP) Distributing Agencies and First Responders
    • Personal Service Settings
    • Report an Overdose
    • Schools
      Toggle Section Schools Menu
      • Ecoles
      • HOT TOPICS
      • Sujets d'actualité
      • School and Classroom Supports
        Toggle Section School and Classroom Supports Menu
        • Body Image at School Classroom
        • Hand Hygiene in Schools Classroom
        • Healthy Eating - Classroom and Educators Supports
        • Human Development and Sexual Health - Classroom and Educator Supports
        • Immunizations - Classroom and Educator Supports
        • Mental Health For Educators
        • Oral Health in Schools for Educators
        • Personal Safety and Injury Prevention in Schools Classroom Supports
        • Physical Activity at School Classroom & Educators
        • Planetary Health Education for Educators
        • Tobacco, Vape, Drugs and Alcohol Prevention for Educators
      • Soutiens pour la classe et les éducatuers
        Toggle Section Soutiens pour la classe et les éducatuers Menu
        • Human Development and Sexual Health - Classroom and Educator Supports
        • Hygiène des mains - soutiens pour des éducateurs
        • Image corporelle - soutiens pour des éducateurs
        • L’activité physique à l’école - soutiens pour des éducateurs
        • L’alimentation saine à l’école - soutiens pour des éducateurs
        • La santé planétaire - soutiens pour des éducateurs
        • Prévention des blessures à l’école - soutiens pour des éducateurs
        • Santé mentale - soutiens pour las classe et les éducateurs
        • Vaccinations - soutiens pour la classe et les éducateurs
      • School and Administrator Page
        Toggle Section School and Administrator Page Menu
        • Body Image for schools and administration
        • Hand Hygiene - Schools and Administration
        • Healthy Eating - School and Administration
        • Human Development and Sexual Health - Schools and Administration
        • Immunizations - For School and Administration
        • Mental Health - Schools and Administration
        • Personal Safety and Injury Prevention - School and Administration Supports
        • Planetary Health Education - Schools and Administration
        • Tobacco, Vape, Drugs and Alcohol Prevention - Schools and Administration
      • Soutien scolaire et administratif
        Toggle Section Soutien scolaire et administratif Menu
        • Developpement humain et sante sexuelle - soutien scolaire et administratif
        • L’activité physique à l’école soutiens administratif
        • L’alimentation saine à l’école - soutiens administratif
        • La santé planétaire - soutiens administatif
        • Santé mentale - soutiens scolaire et administratif
        • Prévention des blessures à l’école - soutien administratif
      • Lending Library and Apps
        Toggle Section Lending Library and Apps Menu
        • Vaping: What’s the Hype?
          Toggle Section Vaping: What’s the Hype? Menu
          • Addiction Activities for Teachers and Students
          • Flavours
          • From Vaping to Smoking?
          • Health Effects
          • Marketing
          • Nicotine and the Brain
          • The Law - Supplying
          • The Tobacco Industry
          • The Law - Property
      • Bibliothéque de prêt
        Toggle Section Bibliothéque de prêt Menu
        • Trousse d’outils sur le vapotage
          Toggle Section Trousse d’outils sur le vapotage Menu
          • Dépendance
          • Du vapotage à la cigarette ?
          • Effets sur la santé
          • La loi – Endroits où il est interdit de fumer et de vapoter
          • La loi – Fournir des produits de vapotage
          • La nicotine et le cerveau
          • L’industrie du tabac
          • Marketing
          • Produits aromatisés
    • Teaching Kitchen

Contact Us

Subscribe to this page

North Bay Parry Sound District Health Unit Footer Logo

  • Website

    • About Us
    • Employment Opportunities
    • News
  • Links

    • Accessibility
    • Privacy
    • Sitemap
    • Staff Intranet
  • Resources

    Increase Contrast

Your lifetime partner in healthy living!

Copyright 2022 North Bay Parry Sound District Health Unit

By GHD Digital

Browser Compatibility Notification

It appears you are trying to access this site using an outdated browser. As a result, parts of the site may not function properly for you. We recommend updating your browser to its most recent version at your earliest convenience.